Fulgent Genetics Finalizes $56.9M Acquisition of Bako Diagnostics and StrataDx

summarizeSummary

Fulgent Genetics announced the completion of its previously disclosed acquisitions of Bako Diagnostics and StrataDx for a combined cash purchase price of approximately $56.9 million, marking a significant step in its strategic transformation.

check_boxKey Events

• Acquisitions Completed

  Fulgent Genetics finalized the acquisition of StrataDx for approximately $13.5 million in cash and substantially all assets of Bako Pathology LP for approximately $43.4 million in cash.

• Total Purchase Price

  The combined cash purchase price for both acquisitions totaled approximately $56.9 million, subject to post-closing adjustments.

• Strategic Diversification

  These acquisitions are part of Fulgent's strategy to transform from a diagnostic business into a fully integrated precision medicine company, following an expected revenue decline in 2026.

• Lease Assumption

  In connection with the Bako acquisition, Fulgent's subsidiary assumed a commercial lease for laboratory and office space in Alpharetta, GA, extending until July 2032.

auto_awesomeAnalysis

This 8-K filing confirms the closing of the substantial acquisitions of Bako Diagnostics and StrataDx, which were initially announced in December 2025. The total cash outlay of approximately $56.9 million represents a material investment for Fulgent Genetics, especially in light of the company's anticipated revenue decline in 2026 due to a major customer insourcing services. The acquisition of these premier pathology and dermatopathology laboratories is a strategic move aimed at diversifying the company's diagnostic business and advancing its goal of becoming a fully integrated precision medicine company. Investors will now focus on the integration process and the financial contributions of the acquired entities to Fulgent's future performance.